Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALM: Tight Control vs Clinical Management in Crohn's Disease
NCT01235689Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2011
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc.. Started Feb 2011; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01235689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01235689.